Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors

ABSTRACT: Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors

PROVIDER: PRJNA575774 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors

Project description:Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors

| PRJNA575773 | ENA

Developmental enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors

Project description:Developmental enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors

| PRJNA478244 | ENA

Developmental enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors

Project description:Most pancreatic neuroendocrine tumors (PNETs) do not produce symptoms of hormonal excess and are hence considered ‘non-functional’. Their clinical behaviors vary widely, emphasizing the need for a robust classification with prognostic power. Using enhancer maps to infer regulatory programs, we find that the large majority of non-functional PNETs fall into two major sub-types –A and B– that reflect alpha and beta endocrine cell ontogeny, respectively. A and B tumors have similar clinical presentations and histology, but express distinct lineage-specifying transcription factors, ARX or PDX1. In immunohistochemistry, 84% of 142 non-functional PNETs expressed one or the other factor, rarely both. Longitudinal data on 104 cases revealed markedly different outcomes, irrespective of MEN1 mutation status: relapse occurred almost exclusively in patients with type A tumors. These findings reveal a robust molecular stratification that provides insight into cellular origins of non-functional PNETs, accurately predicts disease course, and informs clinical decisions and future trial design.

2019-06-12 | GSE116356 | GEO

Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors.

Project description: Not available

| S-EPMC6919319 | biostudies-literature

Small Bowel Neuroendocrine Tumors (Carcinoid Tumors)

Project description:Small Bowel Neuroendocrine Tumors (Carcinoid Tumors)

| PRJNA185380 | ENA

Mesenteric fibrosis in small intestinal neuroendocrine tumors.

Project description:Assessment of mesenteric fibrosis (MF) presence and severity in small-intestinal neuroendocrine tumors (SI-NETs) remains a diagnostic challenge. To explore possible biomarkers for MF presence, a proteomic analysis was performed of the tumor and stroma compartment of primary SI-NETs and paired mesenteric metastasis.

2022-05-20 | PXD029979 | Pride

Proteomic Analysis of Canine Hepatobiliary Neuroendocrine Neoplasms

Project description:Neuroendocrine neoplasms of the gallbladder and liver occur rarely in dogs and humans. A recent reclassification of human neuroendocrine neoplasms by the World Health Organization has refined categorization of these tumors by morphology, replicative indices, and molecular signatures. In humans, these factors correlate with survival outcomes. Improved characterization of these tumors is needed in dogs to identify diagnostic biomarkers and determine therapeutic strategies. To achieve this objective, the proteome of 3 canine hepatobiliary neoplasms was compared to normal canine adrenal and liver tissue from formalin-fixed paraffin-embedded samples. Thirty-two upregulated and 121 downregulated differentially expressed proteins were identified in the hepatobiliary neuroendocrine neoplasm samples. Among the upregulated proteins is galectin-1, a multivalent carbohydrate binding protein known to play a role in lung and pancreatic neuroendocrine neoplasia development and progression in humans. Drugs targeting the galectin family have shown promise as anticancer therapeutics in cervical cancer, prostate cancer, lung and pancreatic neuroendocrine neoplasia in human medicine. Galectin-1 may represent a novel treatment target in hepatobiliary neuroendocrine neoplasia in both humans and dogs.

2023-03-11 | PXD028822 | Pride

Enhancer Signatures of Neuroendocrine Tumors

Project description:<p>Most pancreatic neuroendocrine tumors (PNETs) do not produce symptoms of hormonal excess and are hence considered “non-functional”. Their clinical behaviors vary widely, emphasizing the need for a robust classification with prognostic power. Using enhancer maps to infer regulatory programs, we find that the large majority of non-functional PNETs fall into two major sub-types that reflect alpha and beta endocrine cell ontogeny, respectively. Tumors of the different subtypes have similar clinical presentations and histology, but express distinct lineage-specifying transcription factors, ARX or PDX1. Here we provide the raw ChIP-seq and RNA-seq data of the PNET cohort in this study, as well as ChIP-seq data of ileal carcinoids.</p>

| phs001910 | dbGaP

CHARACTERIZING TOXICITY PATHWAYS OF FLUOXETINE TO PREDICT ADVERSE OUTCOMES IN ADULT PIMEPHALES PROMELAS

Project description:CHARACTERIZING TOXICITY PATHWAYS OF FLUOXETINE TO PREDICT ADVERSE OUTCOMES IN ADULT PIMEPHALES PROMELAS

| PRJNA758289 | ENA

Methylome analysis in pituitary neuroendocrine tumors

Project description:Methylome analysis in pituitary neuroendocrine tumors

| PRJEB50807 | ENA